Navigation Links
Insmed Regains NASDAQ Compliance
Date:5/5/2009

RICHMOND, Va., May 5 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq: INSM), a biopharmaceutical company, today announced that it has received notification from The NASDAQ Stock Market that it has regained compliance with the minimum $1.00 per share bid price requirement, and further, that it currently complies with all other applicable standards for continued listing.

To regain compliance with the bid price rule, the Company was required to evidence a closing bid price of $1.00 per share or more for a period of at least 10 consecutive trading days. On April 29, 2009, the closing price of the Company's common stock was $1.26 per share, the tenth consecutive day the stock price had closed above $1.00 per share.

Insmed will continue to trade on The NASDAQ Capital Market and the previously disclosed delisting proceeding related to its bid price compliance is now closed.

About Insmed

Insmed Inc. is a biopharmaceutical company with unique protein development experience and a proprietary protein platform aimed at niche markets with unmet medical needs. For more information, please visit http://www.insmed.com.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that in the future our common stock may not meet the standards for continued listing on The NASDAQ Stock Market and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2008. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

    Investor Relations Contact:
    Brian Ritchie - FD
    212-850-5683
    brian.ritchie@fd.com

    Media Relations Contact:
    Irma Gomez-Dib - FD
    212-850-5761
    irma.gomez-dib@fd.com


'/>"/>
SOURCE Insmed Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Insmed to Host First Quarter 2009 Conference Call
2. Insmed Announces Agreement With IDIS to Manage Expanded Access Programs for IPLEX(TM)
3. Insmed Announces That NASDAQ Further Extends Temporary Suspension of Minimum Bid Closing Price Rule
4. Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results
5. Insmed to Host Fourth Quarter and Full-Year 2008 Conference Call
6. Insmed Sells Follow-on Biologics Platform to Merck & Co., Inc. for Gross Proceeds of $130 Million
7. Insmed to Present at Sanford C. Bernstein Biosimilars Long View Conference
8. Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008
9. NASDAQs Temporary Suspension of Minimum Bid Closing Price Rules Extends Insmeds Compliance Date to March 20, 2009
10. Insmed Announces That NASDAQ Temporarily Suspends Minimum Bid Closing Price Rule
11. Insmed to Seek Shareholder Approval for Reverse Split
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... 2016 , ... In anticipation of AxioMed’s exclusive cleanroom manufacturing ... President, Jake Lubinski will be traveling to Switzerland from December 5-10. Mr. Lubinski ... and Zurich to discuss the benefits of a viscoelastic disc. AxioMed received CE ...
(Date:12/2/2016)... Dec. 2, 2016  The Multiple Myeloma Research Foundation ... MMRF CoMMpass Study SM —the largest and most comprehensive ... in multiple myeloma—will be presented at the 58 th ... Exposition in San Diego from ... treatment strategies, as well as identify pathways and targets ...
(Date:12/2/2016)... ANGELES , Dec. 2, 2016 CytRx ... and development company specializing in oncology, today announced the ... noted sarcoma surgeon, industry consultant, and private healthcare investor, ... is a healthcare leader with clinical and strategic experience ... , CytRx,s Chairman and CEO. "As one of the ...
(Date:12/2/2016)... ... December 01, 2016 , ... ACEA Biosciences, Inc. announced today ... clinical trials for AC0010 at the World Conference on Lung Cancer 2016, taking place ... on the phase I/II clinical trials for AC0010 in patients with advanced non-small cell ...
Breaking Biology Technology:
(Date:12/6/2016)... Securus Technologies, a leading provider of ... safety, investigation, corrections and monitoring, and the Prison ... (5) year funding commitment by Securus to PEP ... and reentry support to more inmates and their ... the Prison Entrepreneurship Program (PEP) is an independent ...
(Date:11/30/2016)... 30, 2016  higi SH llc (higi) announced ... targeting national brands, industry thought-leaders and celebrity influencers ... audiences for taking steps to live healthier, more ... 2012, higi has built the largest self-screening health ... million people who have conducted over 185 million ...
(Date:11/24/2016)... -- Cercacor today introduced Ember TM Sport Premium ... measure hemoglobin, Oxygen Content, Oxygen Saturation, Perfusion Index, ... approximately 30 seconds. Smaller than a smartphone, using only ... key data about their bodies to help monitor these ... Hemoglobin carries oxygen to muscles. When hemoglobin and ...
Breaking Biology News(10 mins):